

XMReality - Strong order intake

Redeye makes minor adjustments to its estimates but maintains its fair value range and base case. The Q4 2022 report presented a strong order intake, new partnership agreements and upselling, but also a churn of 10%.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

XMReality - Strong order intake